endoxifen

Endoxifen ((E Z)-Endoxifen) 是 Tamoxifen 的关键活性代谢物，能抑制芳香酶的活性，与雌激素受体有较高的亲和力和特异性。它有潜力研究乳腺癌。

Endoxifen E-isomer (E-Endoxifen) 是一种 Endoxifen 的 E-异构体，是 Endoxifen Z-isomer 原料中主要的杂质。Endoxifen E-isomer 具有抗雌激素活性。

Endoxifen Z-isomer (EDX)是 Tamoxifen 重要的代谢产物,在表达 ERα的乳腺癌细胞中发挥抗雌激素作用。它以浓度依赖的方式抑制 hERG, IC50值为1.6μM。

Endoxifen E-isomer hydrochloride (E-Endoxifen hydrochloride) 是 Endoxifen 的 E-异构体，是 Endoxifen Z-isomer 原料中主要的杂质，具有抗雌激素作用。

Endoxifen, also known as N-desmethyl-4-hydroxytamoxifen, is a chemical that is under development for estrogen receptor-positive breast cancer. It is also being evaluated as an antipsychotic for treatment of mania and other psychotic disorders. Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce afimoxifene (4-hydroxytamoxifen) and endoxifen.

Endoxifen hydrochloride，Tamoxifen的主要活性代谢产物，具备较高的对雌激素受体(estrogen receptor)的亲和力和特异性，并能抑制芳香酶活性。它在乳腺癌研究中表现出潜在应用价值。

Endoxifen Z-isomer hydrochloride (Endoxifen HCl) 是Tamoxifen 最重要的代谢产物, 在表达ERα的乳腺癌细胞中发挥抗雌激素作用, Endoxifen HCl 以浓度依赖的方式抑制hERG, IC50值为1.6μM。

SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC(50) values between 5.0 and 68.1 nmol l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.

Pipendoxifene hydrochloride 是雌激素受体的选择性调节剂。

Pipendoxifene, also known as ERA-923, is a new antiestrogen with potential anticancer activity. ERA-923 potently inhibits estrogen binding to ER-alpha (IC50 = 14 nM). In ER-alpha-positive human MCF-7 breast carcinoma cells, ERA-923 inhibits estrogen-stimulated growth (IC50 = 0.2 nM) associated with cytostasis. In vitro, a MCF-7 variant with inherent resistance to tamoxifen (10-fold) or 4-OH tamoxifen (>1000-fold) retains complete sensitivity to ERA-923 . In preclinical models, ERA-923 has an improved efficacy and safety compared with tamoxifen. In the combination with temsirolimus, ERA-923 showed excellent anticancer activity in preclinical models.

Norendoxifen, also known as 4-hydroxy-N, N-didesmethyltamoxifen, is a nonsteroidal aromatase inhibitor of the triphenylethylene group that was never marketed. It is an active metabolite of the selective estrogen receptor modulator tamoxifen.

SS148 is an nsp14 nsp16 MTase inhibitor. It also showed some degree of selectivity against human protein MTases, an indication of great potential for chemical optimization towards more potent and selective inhibitors of coronavirus MTases.

H-87 is a protein kinase inhibitor and vasodilator.

EGFR-IN-42 (Compound 17b) 是一种有效的 EGFR 抑制剂，具有单位数纳摩尔活性。EGFR-IN-42 通过共价键将他莫昔芬或安多昔芬与 EGFR 抑制剂吉非替尼连接起来。EGFR-IN-42 保留 ER 拮抗剂活性和 EGFR 抑制作用。EGFR-IN-42 具有优越的抗癌活性。

EGFR-IN-43 (Compound 17c) 是一种有效的EGFR 抑制剂，具有单位数纳摩尔活性。EGFR-IN-43 通过共价键将他莫昔芬或安多昔芬与EGFR 抑制剂吉非替尼连接起来。EGFR-IN-43 保留 ER 拮抗剂活性和EGFR 抑制作用。EGFR-IN-43 具有优越的抗癌活性。